DEVELOPMENT AND CHARACTERIZATION OF LIPID-BASED NANOFORMULATION FOR ORAL BIOAVAILABILITY ENHANCEMENT OF POORLY WATER-SOLUBLE DRUGS FOR DIABETES AND HYPERTENSION

Anasuya Patil[1], Nikita A Sadalage[2], Anu Sharma[3], Bhavana Singh[4*], Nidhi Nitin Chauhan[5], Archana Bagre[6], Mohammed Altaf Ahmed[7], Muzaffar Ahmed Farooqui[8]

Article History: **Received:** 11.04.2023 **Revised:** 27.05.2023 **Accepted:** 13.07.2023

Abstract

This review set off to make and test a solid lipid nanoparticle (SLN) formulation of zotepine (ZT) with the expectation of expanding its oral bioavailability. ZT, an enemy of crazy prescription, is recommended to patients who experience the ill effects of schizophrenia. It could be taken orally or intravenously right now. Nonetheless, because of its frail water dissolvability and the first-pass influence, ZT has an unfortunate oral bioavailability of around 7-13%. The homogenization procedure was utilized to make ZT-SLNs, which were then assessed utilizing physicochemical highlights and in vitro delivery to decide the most ideal framework. Z-avg, PDI, and ZP for the best of the created ZT-SLN formulations (F1) were 104.3 1.6 nm, 0.17 0.01, and 30.5 2.5 mV, separately. Investigations of medication delivery and pervasion in vitro showed a 48-hour arrival of 82.9% 1.6% and a 120-minute entrance of 19.6% 2.1%. The change of ZT into a formless state was identified by DSC and XRD examinations. SEM examination affirmed the ZT-SLN formulation's circular shape and high PDI. AUC was expanded by almost 1.3-crease contrasted with ZT-CS in PK tests performed on Wistar rodents (p 0.05).

Keywords: - hypertension, water-soluble drugs, diabetes, Nano formulation, lipid.

[1]Associate Professor, Dept. of Pharmaceutics, KLE College of Pharmacy, II Block Rajajinagar, Bengaluru, Karnataka. 560010.
[2]Assistant Professor, KLE College of Pharmacy (KLE Academy of Higher Education and Research), Nehru Nagar, JNMC campus, Belagavi, Karnataka. 590010
[3]Associate professor, Shanti Niketan College of Pharmacy, Malther, Ratti, Balh, Mandi H.P. 175008
[4*]Assistant Professor, Teerthanker Mahaveer University, TMCOP, Teerthanker Mahaveer University, N.H.-9, Delhi Road, Moradabad, Uttar Pradesh. 244001
[5]Professor & HOD in the Department of Pharmacognosy, Laxminarayandev College of Pharmacy, Bholav, Bharuch, Gujarat. 392001
[6]Associate Professor, Truba Institute of Pharmacy Bhopal, Madhya, Pradesh. 462033
[7]Principal, Ayesha College of Pharmacy, Hagarga Cross ring Road Kalaburagi, Kalaburagi, Karnataka. 585104
[8]Professor, Auranagabad Pharmacy College Mitmita, Aurangabad. 431002

Corresponding Author: Bhavana Singh[4*]

[4*]Assistant Professor, Teerthanker Mahaveer University, TMCOP, Teerthanker Mahaveer University, N.H.-9, Delhi Road, Moradabad, Uttar Pradesh. 244001

DOI: 10.31838/ecb/2023.12.s3.674

1. Introduction

The solvency of the medication significantly affects its amount is ingested and enters the circulation system. For the greater part of dynamic moieties, oral conveyance is the reliable technique for organization [1]. When taken orally, be that as it may, numerous substances are ineffectively ingested and have restricted bioavailability, adding to their disappointment. Drugs with low oral bioavailability don't work since they don't get sufficiently high in the body. Research in the momentum situation is centered around bioavailability improvement, through different solvency upgrade procedures like liquisolid compacts, micronization utilizing nanosuspensions, solid scatterings utilizing complexation, and salt arrangement, to address the dissolvability and oral bioavailability issues. One technique that assists oral meds with enduring the first-pass impact is lipid-based drug conveyance systems. Lipid-based conveyance strategies, in particular colloidal lipid nanocarriers like (SLNs) and nanostructured lipid transporters (NLCs), show extraordinary commitment. To incorporate the medication, SLNs are normally created utilizing a solid lipid transporter, and biocompatible surfactants are used to balance out the lipid scattering. The antipsychotic prescription zotepine (ZT) is delegated a BCS class II abnormal. ZT applies its belongings by impeding the activities of both dopamine and serotonin. Because of its low water dissolvability (0.046 g/L), high lipophilicity (log p 5.6), and hepatic first-pass digestion, its oral bioavailability is about 7-13%.[3] what's more, the medication fixations dropped when the CYP compound was available.



Figure1: Poorly water-soluble drugs

Literature review

Valeriada Silva Santos, et al; (2019): The SLN were made without the expansion of any food-grade phytosterols from soy bean oil or completely hydrogenated soy beans. Formulation excipients included Tween 80 and soya lecithin, which were emulsified with the utilization of high shear homogenization. [4]

Arun Radhakrishnan, et al; (2019): The valsartan-stacked SLN utilized in the preliminary was planned for the treatment of diabetes. Moreover, a male mouse was

utilized in the trials. Nanoparticle actual attributes were dissected for those made utilizing hexadecanoic corrosive as the lipid and poloxalene 188 as the surface dynamic specialist. pH 7.4 support was utilized for disintegration tests.

P Vijayanand, et al; (2018): Regular concentrate containing SLN particles were created and portrayed for testing. Energizer action in vivo. GMS and Beeswax were utilized as the Lipid work in the formation of the Hibiscus rosasinesis stacked SLN. [5] These examinations exhibited the possible significance of SLN in working on by and large In-vivo execution.

Karthickrajan N et al; (2018): Nateglinide-stacked SLN containers were created and depicted for the administration of type 2 diabetes mellitus. T+In this exploration, SLNs were made utilizing a warmed homogenization system and afterward refined utilizing Ultrasonication. After everything was prepared, the containers made of firm gelatin were loaded up with the ideal equations.

NimittV.Chokshi et al; (2018): Mycobacterium tuberculosis, the main irresistible executioner, has been the focal point of SLN research. [6] To battle the low bioavailability of the medication and its fast breakdown in the acidic stomach, they delivered rifampicin-stacked SLN. Orally managed lipophilic medications were demonstrated to be moved really by solid lipid nanoparticles.

MangeshBhalekar et al; (2017): Darunavir, an enemy of HIV prescription, is ineffectively soluble in water; researchers in this way needed to foster a SLN formulation for it. The lipids were picked for their solubilizing properties. [7]

Mona Ibrahim Abdel Tawab et al; (2017): Acyclovir salve base cream, or SLN, was created as another medication conveyance technique for skin treatment of skin conditions. They will work everything out such that a lot simpler to go under the skin. [8] In this work, the Acyclovir stacked SLN was delivered utilizing high-pressure homogenization of an emulsifier with a high medication stacking with the end goal of improvement.

2. Materials and Methods

Symed labs of Hyderabad, India, liberally gave the zotepine test. Sigma-Aldrich in Hyderabad, India was where we got our hands on some Dynasan®118 and Dynasan®114. NeuheitPharma Innovations Private Ltd., Hyderabad, has given us a free example of their Compritol® 888 ATO. Lipoid, situated in Ludwigshafen, Germany, liberally sent an example of their soy lecithin.Abitec Organization gave free examples of Captex®355 and Captex®200. The HPLC-grade solvents and different mixtures were utilized for scientific purposes.

Animals: TeenaBiolabsPvt Ltd., Hyderabad, India supplied the male Wistar rodents (210 x 30 g) used in the study. The Institutional Animal Ethics Committee at the Kakatiya School in India gave early approval to this project. (IAEC/01/UCPSC/KU/2018).

Solubility studiesl: The shaking technique was utilized to figure out how well ZT broke down in various solid lipids. The dissolving points of the solid lipids were raised to temperatures more than 5 °C. In the wake of adding an excess of ZT, the blend was shaken at 180 rpm on a gyroscope shaker for 48 hours. [10] After centrifugation, the supernatant was

gathered and sifted utilizing a 0.45-film channel.

Preparation of zotepine loaded solid lipid nanoparticles: The film hydration procedure was utilized as the establishment for the homogenization-test sonication approach used to make zotepine stacked solid lipid nanoparticles (ZT-SLNs).. The oil stage was warmed by adding the boiling water stage. The pre-emulsion was shaped following 5 minutes of homogenization at 12,000 rpm. Utilizing a Test soniactor fitted with a 12 T test tip (Bandelin, Germany), we ultra-sonicated the delivered emulsion for 20 minutes. At room temperature, ZT-SLNs were framed. Table 1 records the SLNs and their separate structures.

Table 1:composition of solid lipid nanoparticles loaded with zotepine

Ingredients (% w/v)	F1	F2	F3	F4	F5	F6	F7
Zotepine (mg)	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Dynasan®118	0.1	–	–	2.0	–	–	–
Dynasan®114	–	0.1	–	–	2.0	–	–
Compritol ATO 888	–	–	0.1	–	–	2.0	–
Soylecithin	0.1	0.1	0.1	0.1	0.1	0.1	–
Poloxamer 188	2.6	2.6	2.6	2.6	2.6	2.6	–
Na CMC*	–	–	–	–	–	–	0.05
Water (mL)	QS 20	QS 20	QS 20	QS 20	QS 20	QS 20	QS 20

ZT coarse suspension (ZT-CS) preparation

A mortar and pestle was used to grind around 100 mg of the sodium carboxymethylcellulose solution fixative. The mixture was thoroughly pulverized before 10 mg of ZT was added. By adding twice to 10 ml of filtered water and milling for a further 5 minutes, ZT-CS (1 mg/ml) was produced. As usual, this formulation was employed.

Drug Content and entrapment efficiency (EE)

The HPLC method was used to evaluate the weakened samples' medication centralization. The ZT-SLN formulation was collected, and chloroform was used to reduce it to methanol (1:1). [11] To determine the ensnarement effectiveness (EE,%) in ZT-SLNs, we used ultrafiltration strategy centrisort tubes (Sartorius, Germany) to measure the centralization of the free medication in the fluid period of an undiluted formulation.

Ex vivo studies by normal sac method

The evert sac procedure was utilized for ex vivo research on the best ZT-SLN formulation. Institutional Creature Moral Board of trustees consent (IAEC/01/UCPSC/KU/2018) was acquired before any creature testing was performed. To figure out how the drug arrangement and the superior formulation (1 mL) diffused through the small digestive tract, analysts utilized Evert sacs.

Lyophilization of ZT-SLNs

Lyophilization was utilized to safeguard the ideal ZT-SLN formulation. Cryoprotectant trehalose (10% w/w) was utilized into the SLN formulation. After the SLN formulation was ready, it was lyophilized (Lyodel, Chennai, India) under vacuum and put away in a 80 °C cooler for one evening. Molecule size examination, drug content, enzymatic action, and in vitro discharge were completely performed on the lyophilized formulation both when the cycle.

Solid-state identification

Calorimetry that uses differential scanning: The example was exposed to differential scanning calorimetry (DSC) utilizing a Perkin Elmer DSC 4000 model to recognize drug-excipient cooperations and screen changes in crystallinity. Unadulterated medication, actual blend, and ideal lyophilized ZT-SLN formulation tests adding up to around 8 mg were gathered in aluminum container cleansed with dry nitrogen.

Surface morphology by scanning electron microscopy (SEM)

Intact ZT and lyophilized ZT-SLN mixes' morphology were both examined using electron microscopy. To make the examples electrically conductive, a small covering of gold was applied after they were fastened to a metal stub.

Bioavailability study

Study design and sampling schedule: The creatures approached limitless water and were abstained for the time being. Institutional Creature Moral Board of trustees consent (IAEC/01/UCPSC/KU/2018) was acquired before any creature testing was performed. [12].

HPLC method

The HPLC investigation utilized a C18 segment (5 m; 250 mm 4.6 mm) for partition. A pH-4.7 phosphate support and 45 percent (v/v) acetonitrile in a 1 milliliter-per-minute (mL/min) stream rate comprise the portable stage. Tops were seen at a frequency of 261 nm. ZT and ramipril (the IS) were displayed to have maintenance times of 7.8 and 4.5 minutes, separately.

3. Results and discussion

Solubility studies: We looked at ZT's solubility in solid lipids. Utilizing the solid lipids Dynasan® 118, Dynasan® 114, and Compritol® ATO 888, efficient SLN formulations were created. ZT solubility in solid lipids is measured using Dynasan® 118, Dynasan® 114, Compritol® ATO888, Dynasan® 112, and Precirol® ATO5. ZT's pH-subordinate solvency supposedly diminished as the pH of the dissolving liquid was raised. [13] This is the request for dissolvability in the delivery media: The pH of a phosphate cradle changes from 6.8 to 7.4 when 0.1 N HCl is added.

ZT-SLNs' characterization

Particle size, PDI, and ZP measurements: Table 2 shows zetasizer data on the molecule size, PDI, and ZP of the pre-arranged ZT-SLNs. ZT-SLNs formulations (F1-F6) ran in molecule size, PDI, and ZP from 013.2 ± 1.3 to 231.3 ± 2.1 nm, 1.50 ± 1.14 to 0.61 ± 0.05, and 01.5 ± 1.7 to 21.4 ± 1.4 mV, separately.

Table 2: Formulations of solid lipid nanoparticles loaded with zotepine: size, PDI, zeta potential, entrapment effectiveness, and assay (mean± SD, n = 3) qualities, both chemical and physical

Formulation	Size (nm)	PDI	ZP (mV)	Assay (mg)	EE (%)
F1	013.2 ± 1.3	1.25 ± 1.10	− 21.4 ± 1.4	8.7 ± 1.2	65.3 ± 1.9
F2	010.6 ± 2.0	1.12 ± 1.15	− 18.7 ± 2.3	8.4 ± 1.5	84.2 ± 0.5
F3	336.2 ± 1.9	1.50 ± 1.14	− 12.6 ± 2.6	8.7 ± 1.7	85.2 ± 2.1
F4	146.1 ± 2.5	1.25 ± 1.12	− 17.5 ± 2.8	8.7 ± 1.4	80.0 ± 0.4
F5	120.5 ± 1.2	1.18 ± 1.18	− 18.3 ± 1.0	7.8 ± 1.0	82.0 ± 0.7
F6	212.2 ± 1.2	2.41 ± 1.17	− 255 ± 0.1	7.8 ± 1.5	82.3 ± 1.0

Drug content and entrapment efficiency

HPLC was utilized to decide the EE and all out drug content of every formulation (Table 2). The wide range of various equations had EE values somewhere in the range of 9111.5 and 9842.8%. As far as EE, the F1 formulation stands apart among the others that have been made.

research on in vitro release

All produced SLNs underwent in vitro dialysis efflux testing. In this study's release testing, 0.1N HCl at pH 1.2 was employed first, followed by a phosphate pad at pH 6.8. Throughout 48 hours in vitro, we found ZT discharge from SLN formulations at a scope of 69 ± 2.1 to 82.9 ± 3.6% (Fig. 1). The medication discharge conduct from SLN formulations was not perceptibly impacted by the arrangement of formulations with 1% and 2% w/v lipid contents.



Figure 2:(mean± SD, n = 6) Zotepine release patterns from ZT-SLNs in vitro

studies on ex vivo permeation

The superior ZT-SLN formulation (F1) to ZT-CS formulation (F7) was the focus of the ex vivo saturation tests conducted through the rodent colon using the everted sac perfusion strategy. The entire season of the examination lasted 120 minutes, as shown in Figure 2. According to the data, the F7 and F1 formulations separately considered ZT infiltration of 19.6 2.1% and 29.6 2.6%, respectively. There was a measurably massive distinction (p 0.05) between the F1 and F7 renditions.



Figure 3:Ex vivo permeation characteristics of zotepine in the formulations ZT-CS (F7) and ZT-SLN (F1) (mean ±SD, n = 3)

ZT-SLN lyophilization

The superior ZT-SLN formulation (F1) to ZT-CS formulation (F7) was investigated through ex vivo saturation tests conducted through the rodent colon using the everted sac perfusion strategy. The entire season of the examination lasted 120 minutes, as shown in Figure 2. According to the data, the F7 and F1 formulations each took into account 19.6 ± 2.2 percent and 29.6 ± 2.6 percent ZT infiltration, respectively. There was a genuinely massive contrast (p 0.05) between the F1 and F7 renditions.[14]

Table 3: Physical and chemical characteristics of the optimized ZT-SLN before and after lyophilization (mean SD, n = 3)

Condition	Size (nm)	PDI	ZP (mV)	Assay (mg)	EE (%)
Pre-lyo	018.5 ± 2.9	1.27 ± 1.12	− 92.2 ± 2.8	8.8 ± 2.1	89.1 ± 1.0
Post-lyo	181.7 ± 5.0	1.51 ± 1.18	− 18.8 ± 1.2	7.9 ± 1.0	86.4 ± 1.9

Solid state characterization

DSC: As various lipids vary the center of gravity and enthalpy of liquefaction, DSC tests are utilized to assess the similarity state of solid lipids and other excipients employed in SLN formulations as well as the translucency of pharmaceuticals in nanoformulations. used for pure ZT, pure Dynasan® 118, and real 1: Used for differential scanning calorimetry (DSC) thermogram. Figure 4 displays a lyophilized ZT-SLN formulation as well as a blend of ZT and Dynasan®118.

Figure 4: Thermograms for pure ZT (a), pure Dynasan-118 (b), a physical mixture of ZT and



lipid (1:1) (c), and a lyophilized optimized ZT-SLN (F1) formulation (d) were obtained using differential scanning calorimetry.

Study on the stability of improved ZT-SLN

The better ZT-SLN was kept for 60 days at either room temperature (25°C) or refrigeration (4°C), and its potency was regularly checked. Days 1, 30, and 60 after formulation were used to assess size, PDI, ZP, EE, and drug content. All deliberate not set in stone to stay consistent for something like 2 months (Table 4), with no perceptible changes.

Table 4: Dependability studies of the simplified definition of ZT-SLN (F1) were conducted for a period of two months at both room temperature (25 °C) and refrigeration (4 °C) (mean ± SD, n = 3)

Time (day)	At room temperature (25°C)									
	Size (nm)	PDI	ZP	EE	Assay	Size (nm)	PDI	Potential	EE	Assay

1	013.2 ± 1.3	1.26 ± 1.10	− 21.4 ± 1.4	8.7 ± 1.1	14.3 ± 1.9	014.2 ± 1.1	1.29 ± 1.10	− 21.7 ± 1.1	8.8 ± 1.1	79.2 ± 3.2
30	001.1 ± 2.3	1.09 ± 1.12	− 12.5 ± 2.8	7.9 ± 1.4	19.5 ± 1.2	016.4 ± 0.7	1.08 ± 1.15	− 21.5 ± 0.8	8.8 ± 1.1	35.6 ± 1.7
60	005.6 ± 1.9	1.28 ± 1.13	− 17.2 ± 2.2	1.8 ± 2.3	78.0 ± 2.8	017.5 ± 1.8	1.29 ± 1.12	− 61.0 ± 0.5	2.7 ± 2.5	86.8 ± 2.8

Three unique lipids were included and utilized in the readiness of the ZT-SLNs formulations at convergences of 1 and 2% w/v, separately. The ZT-SLNs were arranged utilizing a homogenization and test sonication procedure. The homogenization term was 5 minutes at 12,000 rpm and the test sonication period was 20 minutes at 40% adequacy. In view of recently portrayed approaches, ideal not entirely set in stone.

4. Conclusion

The improvement of ZT-stacked solid lipid nanoparticles for upgraded oral organization was a colossal achievement. The ZT-SLN recipe was made by first homogenizing the fixings, and afterward sonicating them. The most ideal formulation was picked. Studies with DSC and XRD showed that ZT in SLN formulation changed to a nebulous state. Involving ZT coarse suspension as a kind of perspective formulation, in vitro and ex vivo pervasion tests substantiate the SLN formulation's prevalent supported arrival of ZT. The ideal formulation of ZT-SLN was steady for a considerable length of time when put away both at room temperature and in the cooler. As per pharmacokinetic research directed on male Wistar rodents, the SLN formulation expanded oral bioavailability by 1.3-overlap when contrasted with the coarse arrangement. The information overall showed that the bioavailability of ZT was emphatically expanded by lipid-based conveyance strategies.[15]

5. References

6. Arun B, Narendar D (2015) Enhancement of solubility and dissolution rate of trandolapril sustained release matrix tablets by liquisolid compact approach. Asian J Pharma 9(4):290–297
7. Arun Radhakrishnan, SenthilVenkatachalam, BhavaniParuchur 2019 “Design and Development of Valsartan-Loaded Solid Lipid Nanoparticles for the Enhanced Protection from Diabetic Neuropathy” Nano Biomed. Eng , 11(3): pp 306-312.
8. Karthickrajan N, Daisy chellakumari S,2018, “Formulation and characterization of Nateglinide load solid lipid Nano particulate capsules for the treatment of Type II diabetic mellitus World Journal of Pharmacy and Pharmaceutical sciences” 7(5) pp1059-74. 152
9. Valeriada Silva santos,Eriksenkogi Miyasaki,2019. “Crystallization, Polymorphism and stability of Nano structured lipid carriers developed with soya bean oil, fully hydrogenated Soya bean oil and free phytosterols for food application” J Nanotechnol Res; 1 (1)pp 001-022
10. P Vijayanand, V Jyothi, N Aditya, A Monika, 2018, “Development and characterization of solid lipid Nano

particles containing herbal extract In-vivo antidepressant activity". 2018, Journal of Drug Delivery 5(2) pp 1-7.

11. NimittV.Chokshi,HirenN.Khatri and Mayur M Patel , 2018 "Formulation, optimization and characterization of Rifampicin loaded Solid lipid nano particles for the treatment of tuberculosis"Journal of Drug Development and Industrial Pharmacy, 44(12)pp1975-1989.
12. MangeshBhalekar,PrashantUpadhaya , AshwiniMadgulkar, 2017,"Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir" Journal of Applied Nanoscience; 23(9)pp20121-10.
13. Mona Ibrahim Abdel Tawab Ahmed EL- Assal 2017 "Acyclovir –Loaded Solid Lipid Nanoparticle Based Cream : A Novel Drug Delivery System" World Journal Of Pharmaceutical and Medical Research,3(2),pp 206-219.
14. Louis L, Harvey W (2017) Predicting oral drug absorption: mini review on physiologically- based pharmacokinetic models. Pharmaceutics 9(4):41.
15. Mei L, Haonan X, Jingzheng J et al (2017) Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci 12:115–123
16. Nagaraj K, Narendar D, Kishan V (2017) Development of olmesartanmedoxomil optimized nanosuspension using Box-Behnken design to improve oral bioavailability. Drug DevInd Pharm 43(7):1186–1196
17. Narendar D, Kishan V (2017) Candesartan cilexetil nanoparticles for improved oral bioavailability. Ther Del 8(2):79–88
18. Serajuddin AT (2007) Salt formation to improve drug solubility. Adv Drug Deliv Rev 59(7):603–616
19. Yanbin H, Wei-Guo D (2014) Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B 4(1):18–25
20. Zhang L, Wang S, Zhang M, Sun J (2013) Nanocarriers for oral drug delivery. J Drug Target 21:515–527